Adc Therapeutics SA Stock News

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland , June 16, 2025 /PRNewswire/ -...

LAUSANNE, Switzerland , June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") finan...

ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable saf...

LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (each, a "Grant"). The Grants were offered as materi...

LAUSANNE, Switzerland , May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: May 21, 2025 Presentation Time: 10:30-10:55 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik...

ADC Therapeutics SA (NYSE:ADCT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Corporate Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Sudan Loganathan - Stephens Operator Good morning, ladies and gentlemen, and...

LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Ca...

ZYNLONTA ®  plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the known profiles of each agent Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m.